SPRY -55% on CRL for intranasal epinephrine: https://finance.yahoo.com/news/fda-issues-complete-response-letter-024900831.html FDA now requests repeat-dose study be completed prior to neffy approval as opposed to previously agreed-upon post-marketing requirement.